Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labelled Ocrelizumab Biosimilar - Anti-MS4A1/CD20 mAb - Research Grade |
---|---|
Source | CAS 637334-45-3 |
Species | Humanized |
Expression system | Mammalian cells |
Molecular weight | 145kDa |
Purity | >95% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | 2H7 |
Reference | PX-TA1162-SIL |
Related Products | PX-P3060 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-nd |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission.
Reviews
Il n’y a pas encore d’avis.